Truscreen Hits 41% Product Sales Growth and Targets US$18.4M UNITAID Programme
Truscreen confirms 41% product sales growth in FY2026
Truscreen Group Limited has delivered on its February 2026 revenue guidance, with product sales reaching approximately NZ$2.4 million in the year ending 31 March 2026, representing 41% growth on FY2025. Total revenue for the period came in at approximately NZ$2.8 million, up around 29% year-on-year and slightly higher than the company’s previous total revenue guidance announced on 26 February 2026.
The revenue acceleration validates the company’s market adoption trajectory and commercial execution across its expanded distributor network. Product sales growth of 41% significantly outpaced total revenue growth, indicating a shift towards higher-margin device and sensor sales relative to other revenue streams.
For investors, this result demonstrates the company’s ability to forecast accurately whilst delivering material revenue expansion in a challenging medtech market.
When big ASX news breaks, our subscribers know first
How AI-enabled cervical screening works
TruScreen’s flagship device, TruScreen Ultra®, uses AI-enabled technology to detect cervical abnormalities in real-time through optical and electrical measurements of cervical tissue. The device eliminates the need for laboratory processing by providing immediate results at the point of care.
This approach removes several traditional screening bottlenecks: failed samples, missed follow-up appointments, patient discomfort, and the requirement for costly specialised personnel and supporting laboratory infrastructure. The technology performs cervical screening without sampling or processing biological tissues.
For investors, TruScreen’s technology addresses a fundamental constraint in underserved markets lacking laboratory infrastructure. This positions the device as a viable solution for regions where traditional cytology-based screening is impractical or unavailable, directly supporting the company’s geographic expansion strategy.
Geographic expansion driving revenue diversification
During FY2026, Truscreen invested in expanding its distributor networks across multiple new markets, with revenue now spread across a wider number of countries compared to prior periods. The company identified four key expansion markets during the year:
- Uzbekistan
- India
- Indonesia
- Selected African markets
These investments are designed to build the critical mass of product adoption and market access required to support sustainable profitability over the medium term. The company currently maintains distributor relationships across 29 countries, with over 200,000 examinations performed using TruScreen devices in FY2024 alone.
For investors, geographic diversification reduces single-market concentration risk and establishes a recurring revenue base across multiple jurisdictions. The 41% product sales growth validates the early returns on this market development investment.
Clinical validation supports market interest
In February 2026, BMC Cancer (Germany) published peer-reviewed results from a clinical study conducted by COGA (Chinese Obstetricians and Gynaecologists Association) involving approximately 15,000 patients over a 4-year period. Management noted this publication has generated positive interest in TruScreen’s AI-enabled technology.
Peer-reviewed clinical evidence strengthens the company’s credibility with healthcare authorities and supports regulatory and market access discussions. Clinical validation of this scale provides distributors and end-users with independent verification of the technology’s performance in real-world settings.
UNITAID funding applications could unlock US$18.4 million revenue opportunity
Following its success with the Zimbabwe National Aids Council cervical screening programme, TruScreen was invited by global and national aid agencies to join a consortium. The company has submitted three applications to UNITAID for funding designed to support the achievement of WHO’s 2030 cervical cancer elimination goals.
Total programme funding amounts to up to US$57.3 million over three years, with potential revenue for TruScreen as consortium lead reaching up to US$18.4 million. Successful applicants will be advised on or around November 2026.
| Detail | Figure |
|---|---|
| Total programme funding | Up to US$57.3 million |
| Funding period | 3 years |
| TruScreen potential revenue | Up to US$18.4 million |
| Decision timing | On or around November 2026 |
For investors, the UNITAID partnership represents a significant potential revenue catalyst aligned with institutional global health funding. The November 2026 decision timing provides a clear near-term catalyst date. If successful, the funding would represent a material revenue stream relative to FY2026’s NZ$2.8 million total revenue base.
WHO 2030 cervical cancer elimination targets
The UNITAID funding applications support the World Health Organisation’s 90-70-90 milestones for cervical cancer elimination by 2030:
- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women screened using a high-performance test by the age of 35, and again by the age of 45
- 90% of women with pre-cancer treated, and 90% of women with invasive cancer managed
TruScreen’s technology directly addresses the screening milestone, positioning it as a point-of-care solution for global health initiatives backed by institutional funding. The company’s device removes the laboratory infrastructure requirement that prevents many underserved regions from achieving the 70% screening target.
The next major ASX story will hit our subscribers first
FY2026 earnings reflect market development investment
The company expects to report an unaudited loss for FY2026 similar to FY2025, which recorded a loss of approximately NZ$2.2 million. Management attributed the loss to additional market access development costs incurred during the year.
These costs reflect the distributor network expansion and geographic diversification outlined earlier in the announcement. The near-term losses are being deployed into revenue-generating market infrastructure, with 41% product sales growth demonstrating early returns on this investment strategy.
For investors, the key question is whether revenue growth can accelerate sufficiently to offset these market development costs over the medium term. The company has stated these investments are designed to build the critical mass required to support sustainable profitability, with the expanded geographic footprint and clinical validation providing potential catalysts for margin improvement.
Get Healthcare News Before the Market Moves
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. The moment companies announce material updates, subscribers get alerts delivered straight to their inbox. Click the “Free Alerts” button at Big News Blast to stay ahead on sector-moving developments.